Cargando…

PDE5 inhibitor drugs for use in dementia

Alzheimer's disease and related dementias (ADRD) remain a major health‐care challenge with few licensed medications. Repurposing existing drugs may afford prevention and treatment. Phosphodiesterase‐5 (PDE5) is widely expressed in vascular myocytes, neurons, and glia. Potent, selective, Food an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hainsworth, Atticus H., Arancio, Ottavio, Elahi, Fanny M., Isaacs, Jeremy D., Cheng, Feixiong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Perspectives
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10520293/ https://www.ncbi.nlm.nih.gov/pubmed/37766832 http://dx.doi.org/10.1002/trc2.12412

Ejemplares similares

Vascular cognitive impairment and dementia: An early career researcher perspective
por: Silva, Nárlon C. Boa Sorte, et al.
Publicado: (2022)

PDE5 inhibitors promote recovery of peripheral neuropathy in diabetic mice
por: Wang, Lei, et al.
Publicado: (2017)

An introduction to therapeutic approaches to vascular cognitive impairment
por: Hainsworth, Atticus H, et al.
Publicado: (2021)

The effect of phosphodiesterase-5 inhibitors on cerebral blood flow in humans: A systematic review
por: Pauls, Mathilde MH, et al.
Publicado: (2017)

PDE5 Exists in Human Neurons and is a Viable Therapeutic Target for Neurologic Disease
por: Teich, Andrew F., et al.
Publicado: (2016)

Clinical trials in vascular cognitive impairment following SPRINT-MIND: An international perspective
por: Elahi, Fanny M., et al.
Publicado: (2023)

ROCK and PDE-5 Inhibitors for the Treatment of Dementia: Literature Review and Meta-Analysis
por: Lee, Dong-Hun, et al.
Publicado: (2022)

Central serous chorioretinopathy treatment with a systemic PDE5 and PDE6 inhibitor (sildenafil)
por: Coleman, D. Jackson, et al.
Publicado: (2020)

Using PDE5 inhibitors for the prevention and treatment of colorectal cancer
por: Browning, Darren D
Publicado: (2015)

New Approaches in Oncology for Repositioning Drugs: The Case of PDE5 Inhibitor Sildenafil
por: Cruz-Burgos, Marian, et al.
Publicado: (2021)

Investigation of PDE5/PDE6 and PDE5/PDE11 selective potent tadalafil-like PDE5 inhibitors using combination of molecular modeling approaches, molecular fingerprint-based virtual screening protocols and structure-based pharmacophore development
por: Kayık, Gülru, et al.
Publicado: (2017)

The efficacy of PDE5 inhibitors in diabetic patients
por: Swiecicka, Agnieszka
Publicado: (2022)

Memory-enhancing effects of GEBR-32a, a new PDE4D inhibitor holding promise for the treatment of Alzheimer’s disease
por: Ricciarelli, Roberta, et al.
Publicado: (2017)

White matter hyperintensities in vascular contributions to cognitive impairment and dementia (VCID): Knowledge gaps and opportunities
por: Alber, Jessica, et al.
Publicado: (2019)

β- but not γ-secretase proteolysis of APP causes synaptic and memory deficits in a mouse model of dementia
por: Tamayev, Robert, et al.
Publicado: (2012)

Reversal of neurobehavioral social deficits in dystrophic mice using inhibitors of phosphodiesterases PDE5A and PDE9A
por: Alexander, M S, et al.
Publicado: (2016)

Current drug therapy of patients with BPH-LUTS with the special emphasis on PDE5 inhibitors
por: Kolontarev, Konstantin, et al.
Publicado: (2016)

Treatment Strategy for Non-Responders to PDE5 Inhibitors
por: Park, Nam Cheol, et al.
Publicado: (2013)

AB041. Evolution of PDE5 inhibitors in Korea
por: Moon, Du Geon
Publicado: (2015)

PDE5 inhibitors enhance the lethality of [pemetrexed + sorafenib]
por: Booth, Laurence, et al.
Publicado: (2017)

CCCDTD5: Reducing the risk of later‐life dementia. Evidence informing the Fifth Canadian Consensus Conference on the Diagnosis and Treatment of Dementia (CCCDTD‐5)
por: Rockwood, Kenneth, et al.
Publicado: (2020)

Determination of Phosphodiesterase Type-5 Inhibitors (PDE-5) in Dietary Supplements
por: Gheorghiu, Oana Ramona Cătălina, et al.
Publicado: (2023)

Repurposing drugs in oncology (ReDO)—selective PDE5 inhibitors as anti-cancer agents
por: Pantziarka, Pan, et al.
Publicado: (2018)

A new precision medicine initiative at the dawn of exascale computing
por: Nussinov, Ruth, et al.
Publicado: (2021)

Established and emerging therapeutic uses of PDE type 5 inhibitors in cardiovascular disease
por: Tzoumas, Nikolaos, et al.
Publicado: (2020)

PDE5 Inhibitors as Potential Tools in the Treatment of Cystic Fibrosis
por: Noel, Sabrina, et al.
Publicado: (2012)

Comparative dissolution study on counterfeit medicines of PDE-5 inhibitors
por: Deconinck, E., et al.
Publicado: (2014)

Computational Study on Selective PDE9 Inhibitors on PDE9-Mg/Mg, PDE9-Zn/Mg, and PDE9-Zn/Zn Systems
por: Sivakumar, Dakshinamurthy, et al.
Publicado: (2021)

A ceRNA approach may unveil unexpected contributors to deletion syndromes, the model of 5q- syndrome
por: Arancio, Walter, et al.
Publicado: (2015)

Role of phosphodiesterase 5 in synaptic plasticity and memory
por: Puzzo, Daniela, et al.
Publicado: (2008)

Identification of pyrazolopyridazinones as PDEδ inhibitors
por: Papke, Björn, et al.
Publicado: (2016)

Recommendations of the 5th Canadian Consensus Conference on the diagnosis and treatment of dementia
por: Ismail, Zahinoor, et al.
Publicado: (2020)

Role of Phosphodiesterase 7 (PDE7) in T Cell Activity. Effects of Selective PDE7 Inhibitors and Dual PDE4/7 Inhibitors on T Cell Functions
por: Szczypka, Marianna
Publicado: (2020)

Caspase-9 mediates synaptic plasticity and memory deficits of Danish dementia knock-in mice: caspase-9 inhibition provides therapeutic protection
por: Tamayev, Robert, et al.
Publicado: (2012)

Phosphodiesterase Type 5 (PDE5) Inhibitors Sensitize Topoisomerase II Inhibitors in Killing Prostate Cancer Through PDE5-Independent Impairment of HR and NHEJ DNA Repair Systems
por: Chang, Jo-Fan, et al.
Publicado: (2019)

Screening and Determination of Synthetic PDE-5 Inhibitors in Adulterated Sexual Enhancement Supplements
por: Jairoun, Ammar Abdulrahman, et al.
Publicado: (2022)

Dr. Bang-Ping Jiann: PDE5 inhibitors in erectile dysfunction
por: Gao, Lucine M.
Publicado: (2016)

PDE5 inhibitor protects the mitochondrial function of hypoxic myocardial cells
por: Jia, Haiyan, et al.
Publicado: (2019)

Treating COPD with PDE 4 inhibitors
por: Brown, William M
Publicado: (2007)

Differential Expression and Function of PDE8 and PDE4 in Effector T cells: Implications for PDE8 as a Drug Target in Inflammation
por: Vang, Amanda G., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_i2b8c6juo21mdvvb44lg37f5ff